A nationwide survey of olanzapine for antiemetic therapy

A nationwide survey of olanzapine for antiemetic therapy - A nationwide survey of olanzapine for antiemetic therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035360

Enrollment

1500

Registered

2018-12-26

Start date

2019-01-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who received high/moderate emetic risk chemotherapy and given olanzapine.

Exclusion criteria

Exclusion criteria: The patients who undergoing another clinical trial.

Design outcomes

Primary

Measure	Time frame
A frequency of discontinuation of olanzapine.	—

Countries

Japan

Contacts

Public ContactToshinobu Hayashi

Fukuoka University Department of pharmacy

toshinobu@fukuoka-u.ac.jp+81928716631

Outcome results